CagriSema: The New GLP 1 and Amylin Combination That May Transform Obesity Treatment Presenters to provide first look at data from REIMAGINE trials of cagrilintide semaglutide for type 2 diabetes management ADA Meeting News CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature Metabolism A new drug combo of semaglutide (GLP 1 receptor agonist) with cagrilintide (amylin analogue) failed to do as well as tirzepatide (GLP 1 GIP receptor agonist). The future of these medicines is hitting different receptors. Novo Nordisk Submits CagriSema for FDA Approval for Obesity Treatment Dr. Jibran Khan R. Ph., CRCP., PhD posted on the topic LinkedIn